The cannabinoid most readers should start with is CBD (cannabidiol). It has the deepest research base of the non-intoxicating options, it stays legal in most US states when it comes from hemp, and a lab report can confirm what is in the bottle. This list sorts the main cannabinoids by how they interact with CB1 and CB2 receptors, how much human research exists, whether they cause a high, and how easy they are to verify with third-party testing.
How this list is organized
- Receptor target: CB1 (mostly brain and nerve tissue) or CB2 (mostly immune tissue), plus non-receptor routes such as serotonin and TRPV1.
- Intoxicating potential: whether the compound produces a psychoactive high.
- Research depth: human trials first, then animal and lab work, then traditional use.
- US legal status: hemp-derived versus marijuana-derived, and state rules that vary.
- Testing: whether a certificate of analysis (COA) can confirm potency and screen for solvents, pesticides, and heavy metals.
CBD (cannabidiol)
CBD is the benchmark non-intoxicating cannabinoid. It shows little direct binding at CB1, and researchers point to several other targets, including serotonin receptors and TRPV1. The FDA approved a purified CBD drug for two rare seizure disorders, which makes it the only cannabinoid with a clear prescription pathway.
Pros
- Large body of research compared with other minor cannabinoids.
- No high at normal serving sizes.
- Widely available as oil, capsule, gummy, or topical.
Cons
- Can interact with drugs that use liver enzymes, including some blood thinners and seizure medicines.
- High doses have been linked to liver enzyme changes in clinical settings.
- Product quality varies, so a COA matters more here than with any other cannabinoid.
Best for: a first purchase, daily use, and anyone who wants no psychoactive effect.
THC (delta-9-tetrahydrocannabinol)
THC is the main intoxicating cannabinoid and a partial agonist at CB1. It is the most studied psychoactive compound in cannabis and appears in prescription drugs for chemotherapy nausea and appetite loss. Federal law classifies it as a controlled substance, so state rules decide access.
Pros
- Strong evidence for nausea, appetite, and some pain states.
- Fast effects when inhaled.
Cons
- Impairment, anxiety, and racing heart in sensitive users.
- Regular high-dose use is linked to dependence and, in people with a family history of psychosis, higher risk of psychotic symptoms.
- Not suitable before driving or at work.
Best for: short-term symptom relief under a clinician who knows your history.
CBG (cannabigerol)
CBG is the precursor molecule that plant enzymes convert into THC and CBD, which is why mature flower holds so little of it. Lab work points to activity at CB1, CB2, and alpha-2 adrenergic receptors. Human trials are still thin.
Pros
- Non-intoxicating in most reports.
- Often sold as a daytime oil for focus or eye pressure.
Cons
- Scarce in raw plant material, so isolates or bred cultivars cost more.
- Claims about gut, skin, and bladder effects rest on animal studies.
Best for: readers who already use CBD and want a non-intoxicating daytime alternative to test.
CBC (cannabichromene)
CBC binds CB2 and several TRP channels rather than CB1. It tends to appear at low levels in hemp and cannabis extracts, and early research looks at inflammation and pain signaling.
Pros
- No intoxicating effect.
- May add to the effect of other cannabinoids in full-spectrum oil.
Cons
- Few human studies.
- Rarely sold alone, so dosing is hard to control.
Best for: full-spectrum users who want a wider cannabinoid profile rather than a single isolate.
CBN (cannabinol)
CBN forms as THC breaks down with heat, light, and time, which is why older flower shows higher levels. It binds CB1 with low strength. The sleep market leans on CBN, but published human sleep trials are limited.
Pros
- Mild and non-intoxicating for most users.
- Pairs well in an evening oil with CBD and a small amount of THC.
Cons
- The sleep reputation runs ahead of the evidence.
- Can push a full-spectrum product over the federal THC limit if it degrades in storage.
Best for: an evening routine when CBD alone has not helped and you accept the research gap.
THCV (tetrahydrocannabivarin)
THCV is a THC analog that acts as a CB1 antagonist at low doses and a CB1 agonist at high doses. Early work looks at appetite and blood sugar, but the effect flips with dose, so the label matters.
Pros
- Non-intoxicating at low servings.
- Studied for metabolic markers in small trials.
Cons
- High servings can become psychoactive.
- Expensive and often mislabeled.
Best for: experienced users tracking appetite or energy who will read the COA and start low.
CBDV (cannabidivarin)
CBDV is a CBD relative that differs by a short side chain. Clinical trials have explored it in autism and epilepsy, which makes it one of the better-researched minor cannabinoids outside THC and CBD.
Pros
- Non-intoxicating.
- Human trial data exists, even if results are early.
Cons
- Hard to find outside specialty brands.
- Price per milligram runs high.
Best for: someone with a specific interest in seizure or neurodevelopmental research who wants a CBD-adjacent option.
Acidic cannabinoids: CBDA and THCA
Raw cannabis holds CBDA and THCA, the acid forms that decarboxylate into CBD and THC when heated. THCA does not cause a high until it converts. Preclinical work on CBDA explores nausea and inflammation, and THCA has early studies on pain and inflammation.
Pros
- THCA is non-intoxicating in raw or unheated form.
- Useful for people who want the raw plant profile.
Cons
- Heat converts them, so baking, vaping, or smoking changes the effect.
- Stability and shelf life are shorter than neutral cannabinoids.
Best for: tincture or capsule users who want a raw profile and will store the bottle away from heat and light.
Minor and emerging cannabinoids
CBL, CBT, and CBCA appear at trace levels in most extracts, and research on them sits at the lab bench. Delta-8 THC, delta-10 THC, and HHC are synthesized or converted compounds sold in hemp shops. Delta-8 is intoxicating, and regulators in several states have moved to restrict it, so treat it as a psychoactive product rather than a CBD substitute.
- Good sign: the COA names the compound, the batch, and the lab.
- Caution: vague labels such as "proprietary blend" hide the actual milligrams.
What a lab report should show
- Potency by cannabinoid, in milligrams per serving and total per container.
- Pesticides, residual solvents, heavy metals, microbials, and mycotoxins.
- A batch or lot number that matches the bottle.
- An accredited lab, ideally ISO 17025.
Use case cheat sheet
- No high, daily baseline: CBD, with CBC or CBG for a wider profile.
- Evening wind-down: CBD plus CBN, keeping total THC under the state limit.
- Raw plant approach: CBDA and THCA in an unheated tincture.
- Strong symptom relief: THC under medical guidance, not self-dosed from a hemp shelf.
- Metabolic or appetite interest: THCV, low dose, with a COA in hand.